A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Castration Resistant Prostate Cancer
NCT02867345 · WITHDRAWN · N/A
We track 3 ClinicalTrials.gov studies led by Peking University. The portfolio skews toward Phase 1 (2 trials).
3 clinical trials sponsored by Peking University.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 2 | 67% |
| N/A | 1 | 33% |
Peking University currently sponsors 3 clinical trials tracked on ReadTheTrial. These span Phase 1, N/A.
Peking University conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.